TapewireFind a company

person · Reporting owner

Stout Jay S

Disclosed activity across 2 companies

Tapewire entity
28789
SEC CIK
0001702969

Export transaction history ↓

Reported relationships

Latest disclosed role at each company.

CompanyLast reported asReport datePublished
Aravive, Inc.VSAR · Entity 114535SVP, Technical OperationsApril 24, 2018April 25, 2018
Immunovant, Inc.IMVT · Entity 3632Chief Technology OfficerOctober 07, 2026October 09, 2026

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

Aravive, Inc.

Report date April 24, 2018 · Filed April 25, 2018

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeDirect185,646 Reported balance After 2018-04-24 transaction · row 1
1 source row

Row 1 · 2018-04-24 · Sale · Disposed 4,854 · Balance 185,646

F1: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of certain RSUs, previously reported in Table I following the date of grant.

Filing footnotes · ownership attribution and instrument terms

F1: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of certain RSUs, previously reported in Table I following the date of grant.

Immunovant, Inc.

Report date October 07, 2026 · Filed October 09, 2026

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeDirect201,532 Ending reported balance After 2026-10-07 transaction · row 2
2 source rows · reconciled sequence

Row 1 · 2026-10-07 · Sale · Disposed 2,213 · Balance 203,128

F1: On April 1, 2025, the holder was granted 76,181 restricted stock units ("RSUs"), as previously reported on a Form 4 filed on April 3, 2025, of which 4,761 of these RSUs vested on October 1, 2026. The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of these RSUs. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person.

F2: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $31.58 - $32.30 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.

Row 2 · 2026-10-07 · Sale · Disposed 1,596 · Balance 201,532

F3: On April 2, 2024, the holder was granted 54,978 RSUs, as previously reported on a Form 4 filed on April 4, 2024, of which 3,437 of these RSUs vested on October 2, 2026. The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of these RSUs. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person.

F2: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $31.58 - $32.30 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.

Filing footnotes · ownership attribution and instrument terms

F1: On April 1, 2025, the holder was granted 76,181 restricted stock units ("RSUs"), as previously reported on a Form 4 filed on April 3, 2025, of which 4,761 of these RSUs vested on October 1, 2026. The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of these RSUs. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person.

F2: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $31.58 - $32.30 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.

F3: On April 2, 2024, the holder was granted 54,978 RSUs, as previously reported on a Form 4 filed on April 4, 2024, of which 3,437 of these RSUs vested on October 2, 2026. The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of these RSUs. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person.

Transaction history

JSON API
Reset

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction dateCompanyActivity / securityShares / unitsReported priceReported valueDetails
October 07, 2026 Filed Oct 9, 2026 21:05 UTC Immunovant, Inc. IMVT · Entity 3632 SaleCommon Stock 1,596 $32.06 $51,167.76
Disclosure

SEC source: 0001702969-26-000012 · wk-form4_1791579957.xml · nonDerivative · entry 2

Stout Jay S · CIK 0001702969 · Chief Technology Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 201,532

F3 · shares: On April 2, 2024, the holder was granted 54,978 RSUs, as previously reported on a Form 4 filed on April 4, 2024, of which 3,437 of these RSUs vested on October 2, 2026. The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of these RSUs. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person.

F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $31.58 - $32.30 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.

Read SEC document
October 07, 2026 Filed Oct 9, 2026 21:05 UTC Immunovant, Inc. IMVT · Entity 3632 SaleCommon Stock 2,213 $32.06 $70,948.78
Disclosure

SEC source: 0001702969-26-000012 · wk-form4_1791579957.xml · nonDerivative · entry 1

Stout Jay S · CIK 0001702969 · Chief Technology Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 203,128

F1 · shares: On April 1, 2025, the holder was granted 76,181 restricted stock units ("RSUs"), as previously reported on a Form 4 filed on April 3, 2025, of which 4,761 of these RSUs vested on October 1, 2026. The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of these RSUs. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person.

F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $31.58 - $32.30 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.

Read SEC document
July 23, 2026 Filed Jul 24, 2026 21:57 UTC Immunovant, Inc. IMVT · Entity 3632 SaleCommon Stock 2,857 $38.69 $110,537.33
Disclosure

SEC source: 0001702969-26-000010 · wk-form4_1784930232.xml · nonDerivative · entry 1

Stout Jay S · CIK 0001702969 · Chief Technology Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 205,341

F1 · shares: On April 17, 2023, the holder was granted 100,000 restricted stock units ("RSUs"), as previously reported on a Form 4 filed on April 19, 2023, of which 6,250 of these RSUs vested on July 17, 2026. The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of these RSUs. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person.

F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $38.18 - $39.05 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.

Read SEC document
July 08, 2026 Filed Jul 10, 2026 20:12 UTC Immunovant, Inc. IMVT · Entity 3632 SaleCommon Stock 77 $39.99 $3,079.23
Disclosure

SEC source: 0001764013-26-000081 · wk-form4_1783714376.xml · nonDerivative · entry 4

Stout Jay S · CIK 0001702969 · Chief Technology Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 208,198

F4 · shares: On April 2, 2024, the holder was granted 54,978 RSUs, as previously reported on a Form 4 filed on April 4, 2024, of which 3,436 of these RSUs vested on July 2, 2026. The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of these RSUs. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person.

F3 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $39.92 - $40.03 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.

Read SEC document
July 08, 2026 Filed Jul 10, 2026 20:12 UTC Immunovant, Inc. IMVT · Entity 3632 SaleCommon Stock 1,399 $39.53 $55,302.47
Disclosure

SEC source: 0001764013-26-000081 · wk-form4_1783714376.xml · nonDerivative · entry 3

Stout Jay S · CIK 0001702969 · Chief Technology Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 208,275

F4 · shares: On April 2, 2024, the holder was granted 54,978 RSUs, as previously reported on a Form 4 filed on April 4, 2024, of which 3,436 of these RSUs vested on July 2, 2026. The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of these RSUs. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person.

F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $38.91 - $39.89 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.

Read SEC document
July 08, 2026 Filed Jul 10, 2026 20:12 UTC Immunovant, Inc. IMVT · Entity 3632 SaleCommon Stock 105 $39.99 $4,198.95
Disclosure

SEC source: 0001764013-26-000081 · wk-form4_1783714376.xml · nonDerivative · entry 2

Stout Jay S · CIK 0001702969 · Chief Technology Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 209,674

F1 · shares: On April 1, 2025, the holder was granted 76,181 restricted stock units ("RSUs"), as previously reported on a Form 4 filed on April 3, 2025, of which 4,761 of these RSUs vested on July 1, 2026. The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of these RSUs. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person.

F3 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $39.92 - $40.03 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.

Read SEC document
July 08, 2026 Filed Jul 10, 2026 20:12 UTC Immunovant, Inc. IMVT · Entity 3632 SaleCommon Stock 1,906 $39.53 $75,344.18
Disclosure

SEC source: 0001764013-26-000081 · wk-form4_1783714376.xml · nonDerivative · entry 1

Stout Jay S · CIK 0001702969 · Chief Technology Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 209,779

F1 · shares: On April 1, 2025, the holder was granted 76,181 restricted stock units ("RSUs"), as previously reported on a Form 4 filed on April 3, 2025, of which 4,761 of these RSUs vested on July 1, 2026. The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of these RSUs. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person.

F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $38.91 - $39.89 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.

Read SEC document
June 26, 2026 Filed Jun 26, 2026 23:45 UTC Immunovant, Inc. IMVT · Entity 3632 SaleCommon Stock 6,723 $38.94 $261,793.62
Disclosure

SEC source: 0001764013-26-000074 · wk-form4_1782517552.xml · nonDerivative · entry 2

Stout Jay S · CIK 0001702969 · Chief Technology Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 211,685

F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $38.76 - $39.13 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.

Read SEC document
June 26, 2026 Filed Jun 26, 2026 23:45 UTC Immunovant, Inc. IMVT · Entity 3632 SaleCommon Stock 33,277 $38.18 $1,270,515.86
Disclosure

SEC source: 0001764013-26-000074 · wk-form4_1782517552.xml · nonDerivative · entry 1

Stout Jay S · CIK 0001702969 · Chief Technology Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 218,408

F1 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $37.74 - $38.56 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.

Read SEC document
April 23, 2026 Filed Apr 24, 2026 20:05 UTC Immunovant, Inc. IMVT · Entity 3632 SaleCommon Stock 2,754 $29.62 $81,573.48
Disclosure

SEC source: 0001764013-26-000055 · wk-form4_1777061153.xml · nonDerivative · entry 1

Stout Jay S · CIK 0001702969 · Chief Technology Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 251,685

F1 · shares: On April 17, 2023, the holder was granted 100,000 restricted stock units ("RSUs"), as previously reported on a Form 4 filed on April 19, 2023, of which 6,250 of these RSUs vested on April 17, 2026. The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of these RSUs. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person.

F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.23 - $30.00 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.

Read SEC document
April 08, 2026 Filed Apr 10, 2026 20:02 UTC Immunovant, Inc. IMVT · Entity 3632 SaleCommon Stock 1,518 $24.83 $37,691.94
Disclosure

SEC source: 0001702969-26-000006 · wk-form4_1775851354.xml · nonDerivative · entry 2

Stout Jay S · CIK 0001702969 · Chief Technology Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 254,439

F3 · shares: On April 2, 2024, the holder was granted 54,978 RSUs, as previously reported on a Form 4 filed on April 4, 2024, of which 3,436 of these RSUs vested on April 2, 2026. The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of these RSUs. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person.

F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $24.54 - $25.39 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.

Read SEC document
April 08, 2026 Filed Apr 10, 2026 20:02 UTC Immunovant, Inc. IMVT · Entity 3632 SaleCommon Stock 8,614 $24.83 $213,885.62
Disclosure

SEC source: 0001702969-26-000006 · wk-form4_1775851354.xml · nonDerivative · entry 1

Stout Jay S · CIK 0001702969 · Chief Technology Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 255,957

F1 · shares: On April 1, 2025, the holder was granted 76,181 restricted stock units ("RSUs"), as previously reported on a Form 4 filed on April 3, 2025, of which 19,045 of these RSUs vested on April 1, 2026. The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of these RSUs. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person.

F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $24.54 - $25.39 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.

Read SEC document
April 07, 2026 Filed Apr 9, 2026 20:19 UTC Immunovant, Inc. IMVT · Entity 3632 GrantStock Option (right to buy) · Derivative 96,851 $0.00 Strike: $24.61 $0.00
Disclosure

SEC source: 0001764013-26-000038 · wk-form4_1775765943.xml · derivative · entry 2

Stout Jay S · CIK 0001702969 · Chief Technology Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 96,851

Underlying: Common Stock · 96,851 shares

Expires 2036-04-07

F2 · derivative.exercise_date: These options were granted pursuant to the Plan. The shares underlying the options will vest as to 25% of the total shares on April 1, 2027 and the balance will vest in thirty-six (36) successive substantially equal monthly installments thereafter, subject to the Reporting Person's continuous service to the Issuer as of such date.

Read SEC document
April 07, 2026 Filed Apr 9, 2026 20:19 UTC Immunovant, Inc. IMVT · Entity 3632 GrantCommon Stock 66,937 $0.00 $0.00
Disclosure

SEC source: 0001764013-26-000038 · wk-form4_1775765943.xml · nonDerivative · entry 1

Stout Jay S · CIK 0001702969 · Chief Technology Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 264,571

F1 · shares: These restricted stock units ("RSUs") were granted pursuant to the Issuer's 2019 Equity Incentive Plan (the "Plan"). Each RSU represents a contingent right to receive one share of common stock upon the vesting of the unit. The RSUs will vest as to 25% of the total shares on April 1, 2027 and the balance will vest in twelve (12) successive substantially equal quarterly installments thereafter, subject to the Reporting Person's continuous service to the Issuer as of such date.

Read SEC document
January 21, 2026 Filed Jan 23, 2026 21:21 UTC Immunovant, Inc. IMVT · Entity 3632 SaleCommon Stock 1,977 $26.03 $51,461.31
Disclosure

SEC source: 0001702969-26-000002 · wk-form4_1769203286.xml · nonDerivative · entry 1

Stout Jay S · CIK 0001702969 · Chief Technology Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 197,634

F1 · shares: On April 17, 2023, the holder was granted 100,000 restricted stock units ("RSUs"), as previously reported on a Form 4 filed on April 19, 2023, of which 6,250 of these RSUs vested on January 17, 2026. The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of these RSUs. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person.

Read SEC document
January 07, 2026 Filed Jan 9, 2026 21:03 UTC Immunovant, Inc. IMVT · Entity 3632 SaleCommon Stock 55 $26.92 $1,480.60
Disclosure

SEC source: 0001764013-26-000002 · wk-form4_1767992586.xml · nonDerivative · entry 2

Stout Jay S · CIK 0001702969 · Chief Technology Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 199,611

F1 · shares: On April 2, 2024, the holder was granted 54,978 restricted stock units ("RSUs"), as previously reported on a Form 4 filed on April 4, 2024, of which 3,436 of these RSUs vested on January 2, 2026. The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of these RSUs. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person.

F3 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.91 - $26.94 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.

Read SEC document
January 07, 2026 Filed Jan 9, 2026 21:03 UTC Immunovant, Inc. IMVT · Entity 3632 SaleCommon Stock 1,148 $26.51 $30,433.48
Disclosure

SEC source: 0001764013-26-000002 · wk-form4_1767992586.xml · nonDerivative · entry 1

Stout Jay S · CIK 0001702969 · Chief Technology Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 199,666

F1 · shares: On April 2, 2024, the holder was granted 54,978 restricted stock units ("RSUs"), as previously reported on a Form 4 filed on April 4, 2024, of which 3,436 of these RSUs vested on January 2, 2026. The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of these RSUs. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person.

F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.90 - $26.89 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.

Read SEC document
October 22, 2025 Filed Oct 24, 2025 20:36 UTC Immunovant, Inc. IMVT · Entity 3632 SaleCommon Stock 2,520 $19.03 $47,955.60
Disclosure

SEC source: 0001764013-25-000143 · wk-form4_1761338213.xml · nonDerivative · entry 1

Stout Jay S · CIK 0001702969 · Chief Technology Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 200,814

F1 · shares: On April 17, 2023, the holder was granted 100,000 restricted stock units ("RSUs"), as previously reported on a Form 4 filed on April 19, 2023, of which 6,250 of these RSUs vested on October 17, 2025. The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of these RSUs. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person.

F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $19.03 - $19.23 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.

Read SEC document
October 08, 2025 Filed Oct 10, 2025 20:01 UTC Immunovant, Inc. IMVT · Entity 3632 SaleCommon Stock 1,585 $16.30 $25,835.50
Disclosure

SEC source: 0001764013-25-000138 · wk-form4_1760126514.xml · nonDerivative · entry 1

Stout Jay S · CIK 0001702969 · Chief Technology Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 203,334

F1 · shares: On April 2, 2024, the holder was granted 54,978 restricted stock units ("RSUs"), as previously reported on a Form 4 filed on April 4, 2024, of which 3,436 of these RSUs vested on October 2, 2025. The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of these RSUs. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person.

F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.06 - $16.48 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.

Read SEC document
July 23, 2025 Filed Jul 25, 2025 21:11 UTC Immunovant, Inc. IMVT · Entity 3632 SaleCommon Stock 2,805 $18.15 $50,910.75
Disclosure

SEC source: 0001764013-25-000115 · wk-form4_1753477896.xml · nonDerivative · entry 1

Stout Jay S · CIK 0001702969 · Chief Technology Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 204,919

F1 · shares: On April 17, 2023, the holder was granted 100,000 restricted stock units ("RSUs"), as previously reported on a Form 4 filed on April 19, 2023, of which 6,250 of these RSUs vested on July 17, 2025. The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of these RSUs. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person.

Read SEC document
July 09, 2025 Filed Jul 11, 2025 20:13 UTC Immunovant, Inc. IMVT · Entity 3632 SaleCommon Stock 1,519 $17.24 $26,187.56
Disclosure

SEC source: 0001764013-25-000108 · wk-form4_1752264819.xml · nonDerivative · entry 1

Stout Jay S · CIK 0001702969 · Chief Technology Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 207,724

F1 · shares: On April 2, 2024, the holder was granted 54,978 restricted stock units ("RSUs"), as previously reported on a Form 4 filed on April 4, 2024, of which 3,436 of these RSUs vested on July 2, 2025. The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of these RSUs. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person.

F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $17.00 - $17.50 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.

Read SEC document
April 23, 2025 Filed Apr 25, 2025 20:17 UTC Immunovant, Inc. IMVT · Entity 3632 SaleCommon Stock 1,925 $14.79 $28,470.75
Disclosure

SEC source: 0001764013-25-000083 · wk-form4_1745612230.xml · nonDerivative · entry 1

Stout Jay S · CIK 0001702969 · Chief Technology Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 209,243

F1 · shares: On April 17, 2023, the holder was granted 100,000 restricted stock units ("RSUs"), as previously reported on a Form 4 filed on April 19, 2023, of which 6,250 of these RSUs vested on April 17, 2025. The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of these RSUs. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person.

Read SEC document
April 09, 2025 Filed Apr 11, 2025 20:08 UTC Immunovant, Inc. IMVT · Entity 3632 SaleCommon Stock 5,004 $12.99 $65,001.96
Disclosure

SEC source: 0001764013-25-000069 · wk-form4_1744402102.xml · nonDerivative · entry 1

Stout Jay S · CIK 0001702969 · Chief Technology Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 211,168

F1 · shares: On April 2, 2024, the holder was granted 54,978 restricted stock units ("RSUs"), as previously reported on a Form 4 filed on April 4, 2024, of which 13,744 of these RSUs vested on April 2, 2025. The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of these RSUs. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person.

F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.75 - $13.26 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.

Read SEC document
April 01, 2025 Filed Apr 3, 2025 20:51 UTC Immunovant, Inc. IMVT · Entity 3632 GrantStock Option (right to buy) · Derivative 107,297 $0.00 Strike: $15.20 $0.00
Disclosure

SEC source: 0001764013-25-000055 · wk-form4_1743713507.xml · derivative · entry 2

Stout Jay S · CIK 0001702969 · Chief Technology Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 107,297

Underlying: Common Stock · 107,297 shares

Expires 2035-04-01

F2 · derivative.exercise_date: The shares underlying the options will vest as to 25% of the shares on April 1, 2026 and the remainder will vest in 36 substantially equal monthly installments over three years thereafter, subject to the Reporting Person's continuous service to the Issuer as of such date.

Read SEC document
April 01, 2025 Filed Apr 3, 2025 20:51 UTC Immunovant, Inc. IMVT · Entity 3632 GrantCommon Stock 76,181 $0.00 $0.00
Disclosure

SEC source: 0001764013-25-000055 · wk-form4_1743713507.xml · nonDerivative · entry 1

Stout Jay S · CIK 0001702969 · Chief Technology Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 216,172

F1 · shares: These restricted stock units ("RSUs") were granted pursuant to the Issuer's 2019 Equity Incentive Plan. Each RSU represents a contingent right to receive one share of common stock upon the vesting of the unit. The RSUs will vest as to 25% of the units on April 1, 2026, and the remainder will vest in substantially equal installments on a quarterly basis over three years thereafter, subject to the Reporting Person's continuous service to the Issuer as of such date.

Read SEC document
January 22, 2025 Filed Jan 24, 2025 21:23 UTC Immunovant, Inc. IMVT · Entity 3632 SaleCommon Stock 2,195 $23.59 $51,780.05
Disclosure

SEC source: 0001764013-25-000019 · wk-form4_1737753791.xml · nonDerivative · entry 1

Stout Jay S · CIK 0001702969 · Chief Technology Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 139,991

F1 · shares: On April 17, 2023, the holder was granted 100,000 restricted stock units ("RSUs"), as previously reported on a Form 4 filed on April 19, 2023, of which 6,250 of these RSUs vested on January 17, 2025. The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of these RSUs. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person.

Read SEC document
October 23, 2024 Filed Oct 25, 2024 20:21 UTC Immunovant, Inc. IMVT · Entity 3632 SaleCommon Stock 2,740 $29.53 $80,912.20
Disclosure

SEC source: 0001764013-24-000178 · wk-form4_1729887693.xml · nonDerivative · entry 1

Stout Jay S · CIK 0001702969 · Chief Technology Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 142,186

F1 · shares: On April 17, 2023, the holder was granted 100,000 restricted stock units ("RSUs"), as previously reported on a Form 4 filed on April 19, 2023, of which 6,250 of these RSUs vested on October 17, 2024. The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of these RSUs. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person.

F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.38 - $29.68 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.

Read SEC document
July 24, 2024 Filed Jul 26, 2024 20:20 UTC Immunovant, Inc. IMVT · Entity 3632 SaleCommon Stock 2,813 $27.76 $78,088.88
Disclosure

SEC source: 0001764013-24-000143 · wk-form4_1722025247.xml · nonDerivative · entry 1

Stout Jay S · CIK 0001702969 · Chief Technology Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 144,926

F1 · shares: On April 17, 2023, the holder was granted 100,000 restricted stock units ("RSUs"), as previously reported on a Form 4 filed on April 19, 2023, of which 6,250 of these RSUs vested on July 17, 2024. The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of these RSUs. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person.

F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.37 - $28.06 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.

Read SEC document
April 24, 2024 Filed Apr 26, 2024 21:20 UTC Immunovant, Inc. IMVT · Entity 3632 SaleCommon Stock 7,239 $28.90 $209,207.10
Disclosure

SEC source: 0001764013-24-000087 · wk-form4_1714166431.xml · nonDerivative · entry 1

Stout Jay S · CIK 0001702969 · Chief Technology Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 147,739

F1 · shares: On April 17, 2023, the holder was granted 100,000 restricted stock units ("RSUs"), as previously reported on a Form 4 filed on April 19, 2023, of which 25,000 of these RSUs vested on April 17, 2024. The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of these RSUs. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person.

Read SEC document
April 02, 2024 Filed Apr 4, 2024 20:39 UTC Immunovant, Inc. IMVT · Entity 3632 GrantStock Option (right to buy) · Derivative 68,723 $0.00 Strike: $30.78 $0.00
Disclosure

SEC source: 0001764013-24-000057 · wk-form4_1712263135.xml · derivative · entry 2

Stout Jay S · CIK 0001702969 · Chief Technology Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 68,723

Underlying: Common Stock · 68,723 shares

Expires 2034-04-02

F2 · derivative.exercise_date: The shares underlying the options will vest as to 25% of the shares on April 2, 2025 and the remainder will vest in 36 substantially equal monthly installments over three years thereafter, subject to the Reporting Person's continuous service to the Issuer as of such date.

Read SEC document
April 02, 2024 Filed Apr 4, 2024 20:39 UTC Immunovant, Inc. IMVT · Entity 3632 GrantCommon Stock 54,978 $0.00 $0.00
Disclosure

SEC source: 0001764013-24-000057 · wk-form4_1712263135.xml · nonDerivative · entry 1

Stout Jay S · CIK 0001702969 · Chief Technology Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 154,978

F1 · shares: These restricted stock units ("RSUs") were granted pursuant to the Issuer's 2019 Equity Incentive Plan. Each RSU represents a contingent right to receive one share of common stock upon the vesting of the unit. The RSUs will vest as to 25% of the units on April 2, 2025, and the remainder will vest in substantially equal installments on a quarterly basis over three years thereafter, subject to the Reporting Person's continuous service to the Issuer as of such date.

Read SEC document
April 17, 2023 Filed Apr 19, 2023 20:23 UTC Immunovant, Inc. IMVT · Entity 3632 GrantStock Option (right to buy) · Derivative 150,000 $0.00 Strike: $15.47 $0.00
Disclosure

SEC source: 0001764013-23-000057 · wf-form4_168193578398335.xml · derivative · entry 2

Stout Jay S · CIK 0001702969 · Chief Technology Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 150,000

Underlying: Common Stock · 150,000 shares

Expires 2033-04-17

F3 · derivative.exercise_date: Shares underlying the options vest over four years, with 25% of the shares underlying the options vesting on April 17, 2024 and the remainder of the shares underlying the options vesting in 12 equal quarterly installments thereafter, subject to the Reporting Person providing continuous service to the Issuer as of each such date.

Read SEC document
April 17, 2023 Filed Apr 19, 2023 20:23 UTC Immunovant, Inc. IMVT · Entity 3632 GrantCommon Stock 100,000 $0.00 $0.00
Disclosure

SEC source: 0001764013-23-000057 · wf-form4_168193578398335.xml · nonDerivative · entry 1

Stout Jay S · CIK 0001702969 · Chief Technology Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 100,000

F1 · security: Represents the number of shares underlying restricted stock units awards ("RSUs").

F2 · shares: The RSUs vest over four years, with 25% of the RSUs vesting on April 17, 2024 and the remainder of the RSUs vesting in 12 equal quarterly installments thereafter, subject to the Reporting Person providing continuous service to the Issuer as of each such date.

Read SEC document
April 24, 2018 Filed Apr 25, 2018 18:10 UTC Aravive, Inc. VSAR · Entity 114535 SaleCommon Stock 4,854 $1.55 $7,523.70
Disclosure

SEC source: 0001209191-18-026137 · doc4.xml · nonDerivative · entry 1

Stout Jay S · CIK 0001702969 · SVP, Technical Operations

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 185,646

F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of certain RSUs, previously reported in Table I following the date of grant.

Read SEC document
December 20, 2017 Filed Dec 22, 2017 17:09 UTC Aravive, Inc. VSAR · Entity 114535 GrantCommon Stock 74,500 $0.00 $0.00
Disclosure

SEC source: 0001209191-17-067107 · doc4.xml · nonDerivative · entry 1

Stout Jay S · CIK 0001702969 · SVP, Technical Operations

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 190,500

F1 · shares: Represents the grant of Restricted Stock Units that vest as follows: 25% of the shares vest on each of December 20, 2018, December 20, 2019, December 20, 2020 and December 20,2021.

Read SEC document
October 06, 2017 Filed Oct 10, 2017 20:17 UTC Aravive, Inc. VSAR · Entity 114535 GrantCommon Stock 70,000 $0.00 $0.00
Disclosure

SEC source: 0001209191-17-056567 · doc4.xml · nonDerivative · entry 1

Stout Jay S · CIK 0001702969 · SVP, Technical Operations

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 116,000

F1 · shares: Represents the grant of Restricted Stock Units that vest as follows: 50% of the shares vest on each of October 6, 2018 and October 6, 2019.

Read SEC document
April 03, 2017 Filed Apr 5, 2017 19:06 UTC Aravive, Inc. VSAR · Entity 114535 GrantStock Option (Right to Buy) · Derivative 75,000 $0.00 Strike: $21.30 $0.00
Disclosure

SEC source: 0001209191-17-025827 · doc4.xml · derivative · entry 2

Stout Jay S · CIK 0001702969 · SVP, Technical Operations

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 75,000

Underlying: Common Stock · 75,000 shares

Expires 2027-04-02

F2 · derivative.exercise_date: 25% of the shares subject to the option become exercisable on April 3, 2018 and 1/48 of the shares subject to the option become exercisable monthly thereafter

Read SEC document
April 03, 2017 Filed Apr 5, 2017 19:06 UTC Aravive, Inc. VSAR · Entity 114535 GrantCommon Stock 45,000 $0.00 $0.00
Disclosure

SEC source: 0001209191-17-025827 · doc4.xml · nonDerivative · entry 1

Stout Jay S · CIK 0001702969 · SVP, Technical Operations

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 46,000

F1 · shares: Represents the grant of Restricted Stock Units that vest as follows: 25% of the shares subject to the Restricted Stock Units vest on each of April 3, 2018, April 3, 2019, April 3, 2020 and April 3, 2021.

Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.